This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Vinay Prasad will be the next director of the FDA's Center for Biologics Evaluat...
The “ConnectING with Carnie” campaign page, hosted within the official Ingrezza ...
This is the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about ...
Human medicines European public assessment report (EPAR): Ocrevus, ocrelizumab, ...
The U.S. Food and Drug Administration announced its intent to expand the use of ...
Experts say market turmoil has made it harder for buyers and sellers to agree on...
Human medicines European public assessment report (EPAR): RoActemra, tocilizumab...
Yet regulatory relief for U.S. expansion could be accompanied by new tariffs and...
Bluebird urged shareholders to back a take-private deal that could close imminen...
Human medicines European public assessment report (EPAR): Vyjuvek, beremagene ge...
Human medicines European public assessment report (EPAR): Herceptin, trastuzumab...
Human medicines European public assessment report (EPAR): Lunsumio, mosunetuzuma...
Human medicines European public assessment report (EPAR): Xydalba, dalbavancin, ...
UPD registration guide for UI and API users
List of medicines currently in PRIME scheme
Human medicines European public assessment report (EPAR): Roctavian, valoctocoge...
Human medicines European public assessment report (EPAR): Bortezomib Sun, bortez...
Human medicines European public assessment report (EPAR): Briumvi, ublituximab, ...
Human medicines European public assessment report (EPAR): Zolgensma, onasemnogen...
Bristol Myers Squibb plans to invest $40 billion across U.S. R&D, technology and...